Compare InMode Ltd (INMD) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Mesoblast Limited — how do they compare? InMode Ltd trades at $14.21 (market cap $809.93M), while Mesoblast Limited trades at $14.29 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 2.2× InMode Ltd's market cap, and InMode Ltd is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 28 Days and Mesoblast Limited for 15 Days on average.
| INMD | MESO | |
|---|---|---|
Market Cap | $809.93M | $1.75B |
Volume | 365,490 | 239,027 |
Sector | Health | Health |
52-Week High | $16.62 | $20.96 |
52-Week Low | $12.76 | $13.19 |
Typical Hold Time | 28 Days | 15 Days |
Enterprise Value | $313.27M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $14.08, up 0.5% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong profitability with 76.5% gross margins and 20.7% net income margin, though Q1 2026 earnings missed expectations. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.
Investment outlook is cautiously optimistic with attractive valuation metrics (P/E 11.6, EV/EBITDA 4.5) offset by near-term revenue stagnation. Key risks include US platform sales decline and management capital allocation concerns. Analyst consensus leans neutral with 45% buy ratings and 55% hold, suggesting potential upside if the acquisition materializes or international growth accelerates.
MESO trades at $13.75, down 1.36% on the day, with a bearish technical signal from moving averages. The company reported a net loss of $102.14 million in 2025, though revenue grew to $120 million in 2026. Recent milestones include FDA approval for a new potency assay and completion of a Phase 3 trial for chronic low back pain, signaling progress in its commercial pipeline.
The outlook is mixed; analyst consensus leans buy (45% buy ratings), but profitability remains a challenge with negative margins. Key risks include high cash burn and competitive pressures, while catalysts hinge on successful commercialization of RYONCIL and upcoming trial results. The stock presents a high-risk, high-reward opportunity in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
